Bli medlem
Bli medlem

Du är här


Galapagos NV: Galapagos receives transparency notifications

Mechelen, Belgium; 26 May 2015 - Galapagos NV (Euronext&NASDAQ: GLPG) received
transparency notifications from the Capital Group Companies, Inc., Fidelity
Management and Research LLC, and Federated Equity Management Company of

Pursuant to Belgian transparency legislation[1], Galapagos received a
transparency notification on 21 May 2015 from the Capital Group Companies,
Inc., who notified that since 19 May 2015, entities under its control held
1,795,935 shares, representing 4.68% of the current 38,403,176 outstanding
Galapagos shares. This is compared to the 1,554,436 shares reported in the
transparency notice Galapagos received from the Capital Group Companies,
Inc., on 5 September 2012.

Galapagos also received a transparency notification on 21 May 2015 from
Fidelity Management and Research LLC, who notified that on 19 May 2015,
entities under its control held 2,732,508 shares, representing 7.12% of
outstanding shares. This is the first transparency notice received from
Fidelity Management and Research LLC.

Galapagos also received a transparency notification on 20 May 2015 from
Federated Equity Management Company of Pennsylvania, who notified that on 14
May 2015, it controlled the voting rights attached to the 2,238,000 shares
(representing 5.83% of outstanding shares) held by funds managed by it. This
is the first transparency notice received from Federated Equity Management
Company of Pennsylvania.

About Galapagos

Galapagos(Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule
and antibody programs in cystic fibrosis, inflammation, and other
indications. In the field of inflammation, AbbVie and Galapagos signed a
collaboration agreement for the development and commercialization
offilgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other inflammatory
diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos reported good activity and a favorable safety profile at
12 weeks in both the DARWIN 1 and 2 trials in RA. AbbVie and Galapagos also
signed a collaboration agreement in cystic fibrosis to develop and
commercialize molecules that address mutations in the CFTR gene.
PotentiatorGLPG1837is currently in a Phase 1 trial, and corrector GLPG2222 is
at the pre-clinical candidate stage. GLPG1205,a first-in-class inhibitor of
GPR84 and fully-owned by Galapagos, is currently being tested in a Phase 2
proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully
proprietary, first-in-class inhibitor of autotaxin, has shown favorable
safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic
pulmonary fibrosis. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and


Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications&IR
Tel: +31 6 2291 6240

Galapagos forward-looking statements

This release may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but are not
always, made through the use of words or phrases such as "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates," "may,"
"will," "could," "stands to," "continues," "we believe," "we intend," as well
as similar expressions. Such forward-looking statements may involve known
and unknown risks, uncertainties and other factors which might cause the
actual results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any historic
or future results, financial conditions, performance or achievements
expressed or implied by such forward-looking statements. Among the factors
that may result in differences are the inherent uncertainties associated with
competitive developments, clinical trial and product development activities,
regulatory approval requirements and estimating the commercial potential of
our product candidates. A further list and description of these risks,
uncertainties and other risks can be found in the company's Securities and
Exchange Commission filing and reports, including in the company's prospectus
filed with the SEC on May 14, 2015 and future filings and reports by the
company. Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
---------------------------------------[1] Belgian Act of 2 May 2007 on the disclosure of major
shareholdings in issuers whose shares are admitted to trading on a regulated


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.